Castle Biosciences Inc

NASDAQ:CSTL   9:49:20 AM EDT
80.25
+1.08 (+1.36%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.62B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$15.86 Million
Adjusted EPS-$0.12
See more estimates
10-Day MA$77.75
50-Day MA$62.68
200-Day MA$47.19
See more pivots

CASTLE BIOSCIENCES INC Stock, NASDAQ:CSTL

820 S FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD, TX 77546
United States of America
Phone: 866-788-9007
Number of Employees:

Description

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.